Amphastar Pharmaceuticals (AMPH) Projected to Post Quarterly Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) will likely be releasing its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Amphastar Pharmaceuticals to post earnings of $0.71 per share and revenue of $173.42 million for the quarter.

Amphastar Pharmaceuticals Trading Up 0.2%

Shares of AMPH stock opened at $21.44 on Wednesday. The business’s 50 day moving average is $23.56 and its two-hundred day moving average is $26.50. Amphastar Pharmaceuticals has a twelve month low of $20.39 and a twelve month high of $53.96. The company has a market capitalization of $1.01 billion, a P/E ratio of 7.77 and a beta of 0.76. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AMPH. Wells Fargo & Company lowered their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus target price of $32.33.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Amphastar Pharmaceuticals by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock worth $652,000 after purchasing an additional 613 shares in the last quarter. Intech Investment Management LLC boosted its position in Amphastar Pharmaceuticals by 43.0% during the first quarter. Intech Investment Management LLC now owns 60,289 shares of the company’s stock worth $1,748,000 after purchasing an additional 18,133 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in Amphastar Pharmaceuticals by 82.0% during the first quarter. AQR Capital Management LLC now owns 53,638 shares of the company’s stock worth $1,555,000 after purchasing an additional 24,167 shares in the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.